Detailed Narrative
Strong Q3 & 9 Months FY26 Financial Performance
Windlas Biotech delivered robust financial results for Q3 FY26, with revenue from operations growing 20% YoY to INR233 crores. This marks the 12th consecutive quarter of achieving the highest ever revenue. For the first nine months of FY26, the company reported a 19% YoY revenue growth, reaching INR666 crores, and an EPS of INR24.02, representing a 12% YoY increase. EBITDA for 9M FY26 stood at INR89 crores (13.3% of revenue), with PAT at INR60 crores (9% of revenue).
Key Segmental Growth Drivers
The Generic Formulations CDMO vertical was a primary growth engine, expanding by 23% in Q3 FY26 and 20% for the nine-month period, driven by an expanding customer base and new product launches. The Exports vertical also demonstrated strong momentum, growing 36% in Q3 FY26 and 29% for 9M FY26, through increased penetration into RoW and semi-regulated markets. While the Trade Generics and Institutional verticals grew 18% for 9M FY26, their Q3 FY26 growth was a more modest 7%.
Infrastructure Expansion and Future Capacity
The company's strategic investments in infrastructure are progressing well, with Plant 6 expected to achieve mechanical completion by the end of FY26. The remaining capex for Plant 6 is approximately INR10 crores out of a total INR50-60 crores. Upon completion, Plant 6 is projected to increase the company's revenue capacity to INR1,000 crores (excluding injectables), with an additional INR100 crores from injectables. Commercial operations for Plant 6 are anticipated to commence in H1 FY27, with an estimated annual depreciation of INR9-10.8 crores.
Impact of Regulatory Environment and Industry Consolidation
Management highlighted the significant impact of Schedule M implementation, noting that the government's strict enforcement has led to inspections and closures for non-compliant players. This regulatory pressure🌐 is expected to drive consolidation in the highly fragmented CMO industry, benefiting organized and quality-focused players like Windlas Biotech. The company emphasizes capability building, talent, and robust systems as key differentiators in this evolving landscape.
Capital Allocation and Growth Philosophy
Windlas Biotech maintains a debt-free balance sheet and prioritizes internal accruals for capex, such as the ongoing Plant 6 expansion. While the company is cash-rich, it is not risk-averse and is open to taking on debt for strategic acquisitions that align with its long-term growth objectives, particularly if capacity utilization in injectables reaches high levels. The core philosophy revolves around disciplined execution, diversification, operational efficiencies, and talent development to create long-term shareholder value.